Tel Aviv - Delayed Quote ILA

Kadimastem Ltd (KDST.TA)

2,079.00
-122.00
(-5.54%)
At close: May 22 at 5:24:24 PM GMT+3

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ILA.
NameTitlePayExercisedYear Born
Mr. Ronen Twito CPA CEO & Executive Chairman 421k -- 1975
Mr. Uri Ben-Or Chief Financial Officer 265k -- 1970
Prof. Michel Revel M.D., Ph.D. Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director 480k -- 1938
Mr. Yossi Ben-Yossef Honorary President & Strategic Consultant 1.14M -- 1957
Mr. Olivier Samuel VP of European Business Development & Director 146k -- 1974

Kadimastem Ltd

Pinchas Sapir 7
Ness Ziona, 74140
Israel
972 73 797 1600 https://www.kadimastem.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
11

Description

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.

Corporate Governance

Kadimastem Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.